Advancing the next generation of kidney care for the Central Savannah River Area, where rigorous, ethically governed nephrology trials give our patients first access to tomorrow's therapies.
Southeastern Clinical Research is the dedicated trials arm of Nephrology Associates, PC. We exist to bring rigorously studied, next-generation kidney therapies to the people of the CSRA, years before they reach general practice, without ever compromising the safety, dignity, or consent of the patients who make that progress possible.
Every study is governed by an independent Institutional Review Board, run by a Good Clinical Practice trained team, and overseen by the same board-certified nephrologists who care for our patients every day. Research here is not separate from care. It is an extension of it.
Matthew Diamond, DO · Director, Southeastern Clinical Research
Our investigators concentrate on the conditions that drive the greatest burden of kidney disease across the Southeast.
Disease-modifying therapies aimed at slowing progression and protecting function across CKD stages.
ProgressionTrials of agents that protect the diabetic kidney, including next-generation SGLT2 and non-steroidal MRA pathways.
MetabolicStudies at the intersection of heart and kidney disease, where the two most often fail together.
CardiorenalInvestigational immunomodulatory therapy for IgA nephropathy, lupus nephritis, and FSGS.
ImmuneNovel approaches to the anemia and mineral-bone complications that accompany advanced kidney disease.
ComplicationsTrials targeting the difficult-to-control blood pressure that accelerates kidney decline.
VascularJoining a study is a personal decision, and an entirely voluntary one. For many of our patients, it means closer monitoring, more time with the care team, and a chance to help the next person with kidney disease.
Carefully selected investigational therapies, years before they reach general use.
Additional labs, visits, and study-team attention throughout your participation.
Study-related visits, tests, and the investigational therapy are provided at no cost.
Participation is voluntary, fully consented, and you may withdraw at any time.
A snapshot of representative trials. Specific eligibility is confirmed by our study team. Listings update as protocols open and close.
A randomized study of a disease-modifying agent in adults with stage 3–4 chronic kidney disease and proteinuria.
Evaluating a next-generation therapy to slow decline of kidney function in type 2 diabetes.
An investigational immunomodulator for biopsy-confirmed IgA nephropathy with persistent proteinuria.
Refer a patient for a research evaluation and you stay informed at every step. We confirm eligibility, manage all study-related care, and report back to you directly, while your patient remains yours.